Press release
Retinitis Pigmentosa Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Retinitis Pigmentosa Pipeline
Explore our comprehensive Retinitis Pigmentosa Pipeline Report to stay informed about the latest advancements. Download copy now @ Retinitis Pigmentosa Pipeline Outlook- https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Retinitis Pigmentosa Pipeline Report
• In September 2024:- Janssen Research & Development LLC- Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene. A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
• In September 2024:- AAVantgarde Bio Srl- A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa. The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
• DelveInsight's Retinitis Pigmentosa pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Retinitis Pigmentosa treatment.
• The leading Retinitis Pigmentosa Companies such as Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye, and others.
• Promising Retinitis Pigmentosa Therapies such as EA-2353, BS01, CPK850, hRPC, SPVN06, RST-001, and others.
Dive into our Retinitis Pigmentosa Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Retinitis Pigmentosa Treatment Therapies- https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Retinitis Pigmentosa Emerging Drugs Profile
• BIIB-112: Biogen
BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.
• QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals
QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.
Download the Retinitis Pigmentosa Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Retinitis Pigmentosa Clinical Trials Assessment- https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type
Retinitis Pigmentosa Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Dive into our detailed Retinitis Pigmentosa Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Retinitis Pigmentosa Products, Companies, and Unmet Needs- https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Retinitis Pigmentosa Pipeline Report
• Coverage- Global
• Retinitis Pigmentosa Companies- Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye, and others.
• Retinitis Pigmentosa Therapies- EA-2353, BS01, CPK850, hRPC, SPVN06, RST-001, and others.
• Retinitis Pigmentosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Retinitis Pigmentosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Gain valuable insights into emerging therapies and innovations with our Retinitis Pigmentosa Pipeline Report @ Retinitis Pigmentosa Market Drivers and Barriers, Future Perspectives and Analyst Views- https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Retinitis Pigmentosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Retinitis Pigmentosa - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Retinitis Pigmentosa Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug name: Company name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BIIB-112: Biogen
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. N-acetylcysteine-amide: Nacuity Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. SPVN 06: SparingVision
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Retinitis Pigmentosa Key Companies
23. Retinitis Pigmentosa Key Products
24. Retinitis Pigmentosa- Unmet Needs
25. Retinitis Pigmentosa- Market Drivers and Barriers
26. Retinitis Pigmentosa- Future Perspectives and Conclusion
27. Retinitis Pigmentosa Analyst Views
28. Retinitis Pigmentosa Key Companies
29. Appendix
List of Top Selling Market Research Reports in 2024
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
pigment epithelial detachment market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Neuroendocrine Tumor Market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market
medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
keloid market- https://www.delveinsight.com/report-store/keloid-market
mouth neoplasms market- https://www.delveinsight.com/report-store/mouth-neoplasms-market
urinary retention market- https://www.delveinsight.com/report-store/urinary-retention-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
embolotherapy market- https://www.delveinsight.com/report-store/embolotherapy-market
skin neoplasm market- https://www.delveinsight.com/report-store/skin-neoplasms-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
wilms tumor market- https://www.delveinsight.com/report-store/wilms-tumor-market
rhabdomyosarcoma market- https://www.delveinsight.com/report-store/rhabdomyosarcoma-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinitis Pigmentosa Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3687180 • Views: …
More Releases from DelveInsight Business Research LLP
Atopic Dermatitis Market to Witness Growth by 2034 | Amgen, Kyowa Kirin, Dermira …
DelveInsight's "Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Atopic Dermatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atopic Dermatitis market size…
Acute Lymphocytic Leukemia Treatment Market Size, Forecast, and Companies 2034
DelveInsight's, "Acute Lymphocytic Leukemia Pipeline Insight 2024" report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request…
Atrial Flutter Market to Rise, 2032 | Acutus Medical, ARCA Biopharma, Adagio Med …
DelveInsight's "Atrial Flutter Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Atrial Flutter, historical and forecasted epidemiology as well as the Atrial Flutter market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Atrial Flutter market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atrial Flutter market size…
Encephalitis Market to Rise, 2032 | Merck, Pfizer, GlaxoSmithKline, expected to …
DelveInsight's "Encephalitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Encephalitis, historical and forecasted epidemiology as well as the Encephalitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Encephalitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Encephalitis market size from 2019 to 2032, segmented…
More Releases for Retinitis
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Retinitis Pigmentosa (RP) Market Focusing on intrinsic limitations 2025
Global Retinitis Pigmentosa (RP) Market: Snapshot
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise.
Request Sample Copy of…
Retinitis Pigmentosa (Retinitis) Industry Market Expected To Grow At High Cagr D …
Overview
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740087-retinitis-pigmentosa-retinitis-pipeline-review-h2-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive…
Market Research Focuses on Retinitis Pigmentosa (Retinitis) Market Pipeline Revi …
"The Report Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision…
Global Cytomegalovirus Retinitis Market Size, Share | MarketResearchReports.biz
Latest industry research report on: Global Cytomegalovirus Retinitis Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Cytomegalovirus (CMV) Retinitis is caused by cytomegalovirus infection, which is a herpes-type virus that affects the retina of the human eye among patients having a weak immune system that could be due to conditions such as AIDS, leukemia and/or pregnancy. Symptomatic conditions include floaters, flashes, and blind spots besides…
Retinitis Pigmentosa (Retinitis) Pipeline Insight and Therapeutic Assessment Rev …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Retinitis Pigmentosa (Retinitis)-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Retinitis Pigmentosa (Retinitis). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Retinitis Pigmentosa (Retinitis) by development stage, therapy…
